Re: New Phase 1 NCI trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: New Phase 1 NCI trial

in response to

New Phase 1 NCI trial

jonzobot

posted on May 24, 2023 07:09PM

That's good news, the more paid trials the better , capacebitine is owned by Genetech, interesting, maybe another possible partner or buyer of Zenith

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply